Genscript Biotech Corporation (GNNSF)
USD 1.5
(-21.0%)
USD 1.5
(-21.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 825.34 Million USD | 9.52% |
| 2022 | 731.83 Million USD | 12.29% |
| 2021 | 651.73 Million USD | 45.51% |
| 2020 | 447.88 Million USD | 47.49% |
| 2019 | 303.67 Million USD | 102.68% |
| 2018 | 149.83 Million USD | 146.72% |
| 2017 | 60.73 Million USD | 21.94% |
| 2016 | 49.8 Million USD | 9.06% |
| 2015 | 45.66 Million USD | 27.5% |
| 2014 | 35.81 Million USD | 17.68% |
| 2013 | 30.43 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 228.87 Million USD | 0.0% |
| 2024 Q1 | 228.87 Million USD | -43.78% |
| 2023 Q2 | 393.01 Million USD | 81.47% |
| 2023 Q1 | 216.57 Million USD | -45.99% |
| 2023 FY | 801.53 Million USD | 9.52% |
| 2023 Q4 | 407.08 Million USD | 118.24% |
| 2023 Q3 | 186.52 Million USD | -52.54% |
| 2022 Q3 | 168.19 Million USD | -49.9% |
| 2022 Q2 | 335.73 Million USD | 68.14% |
| 2022 Q1 | 199.67 Million USD | -44.6% |
| 2022 FY | 731.83 Million USD | 12.29% |
| 2022 Q4 | 401 Million USD | 138.43% |
| 2021 Q4 | 360.4 Million USD | 39.6% |
| 2021 Q1 | 143.85 Million USD | -46.43% |
| 2021 FY | 651.73 Million USD | 45.51% |
| 2021 Q3 | 258.17 Million USD | -11.21% |
| 2021 Q2 | 290.77 Million USD | 102.14% |
| 2020 Q4 | 268.53 Million USD | 92.94% |
| 2020 Q2 | 191.23 Million USD | 43.78% |
| 2020 Q1 | 133.01 Million USD | -31.06% |
| 2020 FY | 447.88 Million USD | 47.49% |
| 2020 Q3 | 139.17 Million USD | -27.22% |
| 2019 Q3 | 90.51 Million USD | -24.64% |
| 2019 Q4 | 192.93 Million USD | 113.15% |
| 2019 FY | 303.67 Million USD | 102.68% |
| 2019 Q1 | 60.26 Million USD | 49.01% |
| 2019 Q2 | 120.1 Million USD | 99.3% |
| 2018 Q3 | 40.44 Million USD | 24.62% |
| 2018 Q2 | 32.45 Million USD | 0.0% |
| 2018 Q4 | 40.44 Million USD | 0.0% |
| 2018 Q1 | 32.45 Million USD | 54.85% |
| 2018 FY | 149.83 Million USD | 146.72% |
| 2017 Q3 | 20.95 Million USD | 66.71% |
| 2017 FY | 60.73 Million USD | 21.94% |
| 2017 Q4 | 20.95 Million USD | 0.0% |
| 2017 Q2 | 12.57 Million USD | 0.0% |
| 2017 Q1 | 12.57 Million USD | 4.23% |
| 2016 Q1 | 9.93 Million USD | 30.89% |
| 2016 FY | 49.8 Million USD | 9.06% |
| 2016 Q4 | 12.06 Million USD | 0.0% |
| 2016 Q3 | 12.06 Million USD | 21.45% |
| 2016 Q2 | 9.93 Million USD | 0.0% |
| 2015 Q3 | 7.58 Million USD | -20.86% |
| 2015 Q1 | 9.58 Million USD | -4.08% |
| 2015 Q4 | 7.58 Million USD | 0.0% |
| 2015 FY | 45.66 Million USD | 27.5% |
| 2015 Q2 | 9.58 Million USD | 0.0% |
| 2014 Q1 | 8.07 Million USD | 0.0% |
| 2014 FY | 35.81 Million USD | 17.68% |
| 2014 Q4 | 9.99 Million USD | 0.0% |
| 2014 Q3 | 9.99 Million USD | 23.76% |
| 2014 Q2 | 8.07 Million USD | 0.0% |
| 2013 FY | 30.43 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -61703.568% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -16269.234% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -2692.759% |
| Nascent Biotech, Inc. | 2.22 Million USD | -36912.95% |
| Rebus Holdings, Inc. | 664 Thousand USD | -124198.795% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -2115.351% |
| Qrons Inc. | 643.67 Thousand USD | -128123.317% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -211762.432% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -1336.88% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -198548.789% |
| Skye Bioscience, Inc. | 13.54 Million USD | -5992.201% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -851.021% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -16682.403% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -315246.584% |
| SQZ Biotechnologies Company | 85.61 Million USD | -863.973% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -28201.697% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -54853.362% |
| Mesoblast Limited | 5.9 Million USD | -13884.141% |
| Marizyme, Inc. | 19.23 Million USD | -4189.767% |
| Genus plc | 147.7 Million USD | -458.798% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -9301.094% |
| Pharming Group N.V. | 225.49 Million USD | -266.021% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -40186.132% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -61421.902% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -9797.398% |
| ContraFect Corporation | 56.88 Million USD | -1350.797% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -18620.921% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -55713.551% |
| IMV Inc. | 37.7 Million USD | -2088.706% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -29478.437% |
| MultiCell Technologies, Inc. | 567.42 USD | -145455470.829% |
| ONE Bio Corp. | 6.44 Million USD | -12708.16% |
| Accustem Sciences Inc. | 3.74 Million USD | -21930.211% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -860.316% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -155050.932% |
| Q BioMed Inc. | 3.43 Million USD | -23916.1% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -3239.446% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -31311.497% |
| Biomind Labs Inc. | 994.18 Thousand USD | -82917.395% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -730.91% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -46803.127% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -12185.534% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -44169.324% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 3301476.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -5055.102% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -44875.546% |
| GB Sciences, Inc. | 1.42 Million USD | -58001.99% |
| Alpha Cognition Inc. | 9.7 Million USD | -8403.791% |
| HST Global, Inc. | 140.9 Thousand USD | -585636.692% |
| CSL Limited | 3.44 Billion USD | 76.07% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -73269.781% |
| Halberd Corporation | 74.84 Thousand USD | -1102681.86% |
| Enzolytics Inc. | 2.17 Million USD | -37768.38% |
| Agentix Corp. | 1.37 Million USD | -60066.968% |
| Resverlogix Corp. | 12.71 Million USD | -6392.637% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -22507.785% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 46.18% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -78955.939% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -34218.78% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -52158.295% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -24139.327% |
| AVAX Technologies, Inc. | 7.31 Million USD | -11190.208% |
| Zenith Capital Corp. | 8.94 Million USD | -9128.939% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -4737538.482% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -33514.56% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -481124.892% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -42866.392% |
| Kadimastem Ltd | 2.41 Million USD | -34145.048% |
| Helix BioMedix, Inc. | 1.97 Million USD | -41752.422% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -7494.957% |
| BioStem Technologies, Inc. | 22.97 Million USD | -3492.388% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -454672.571% |
| LadRx Corporation | 3.81 Million USD | -21552.394% |
| Cell Source, Inc. | 4.32 Million USD | -18981.572% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -89270.337% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -89270.337% |
| NovAccess Global Inc. | 2.46 Million USD | -33358.612% |
| Affymax, Inc. | 39.38 Million USD | -1995.526% |
| Itoco Inc. | 919.14 Thousand USD | -89694.95% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -19372.944% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -73657.283% |
| Mobile Lads Corp. | 554.54 Thousand USD | -148732.378% |
| CytoDyn Inc. | 18.05 Million USD | -4470.517% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -3279108.55% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -374923.401% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -58031.332% |
| SYBLEU INC | 160.87 Thousand USD | -512931.154% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -45340.451% |
| International Stem Cell Corporation | 5.27 Million USD | -15558.205% |
| Bioxytran, Inc. | 3.82 Million USD | -21505.032% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1567743.167% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -4057040.048% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -2175.807% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -50910.136% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -112064.276% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -26429.862% |
| Neutra Corp. | 243.82 Thousand USD | -338404.067% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -4627.868% |
| PureTech Health plc | 144.59 Million USD | -470.789% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -3928.055% |
| IXICO plc | 4.7 Million USD | -17434.396% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -9282.108% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -600.941% |
| CSL Limited | 3.89 Billion USD | 78.799% |
| Cellectis S.A. | 97.32 Million USD | -748.072% |